newsfilter
← Latest News
GlobeNewswire·

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

QNRX
  • Quoin Pharmaceuticals received a Notice of Allowance from the USPTO for U.S. Patent Application No. 18/428,570 titled "Combination Treatment for Netherton Syndrome."
  • The allowed patent claims cover a method of treating Netherton Syndrome using a topical serine protease inhibitor, dipalmitoyl hydroxyproline, combined with an anti-inflammatory agent.
  • The patent specifically includes treatment for patients carrying SPINK5 mutations, the genetic cause of Netherton Syndrome, with application to skin lesions on the arms & lower legs.
  • The patent will be granted upon payment of the required issue fee.
  • QRX003 (QYLEKI™) is Quoin's investigational topical treatment for Netherton Syndrome, which currently holds Orphan Drug, Rare Pediatric Disease, & Fast Track designations in the U.S., plus Orphan Drug Designation in the EU & Japan.
  • If approved, QRX003 has the potential to become the first approved treatment for Netherton Syndrome, a rare genetic skin disease with no currently approved therapies.
  • The pivotal Phase 3 study for QRX003 is expected to initiate in the second half of 2026, with a potential New Drug Application (NDA) filing scheduled for 2027.